
|Articles|November 1, 2007
B&L merger approved
Bausch & Lomb's shareholders have voted to approve a merger with Warburg Pincus.
Advertisement
Bausch & Lomb's shareholders have voted to approve a merger with Warburg Pincus.
In accordance with the terms of the merger, each outstanding share of common and Class B stock will be cancelled and converted into the right to receive $65 in cash, without interest, less any applicable withholding taxes.
The merger is expected to close early in the fourth quarter of this year.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
2
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
3
FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD
4
FLORetina 2025: Weight and PMA drive foveal maturation in preterm infants
5












































